PhaseBio Appoints Alex C. Sapir to Board of Directors
February 13 2020 - 4:01PM
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a
clinical-stage biopharmaceutical company focused on the development
and commercialization of novel therapies for cardiopulmonary
diseases, today announced the appointment of Alex C. Sapir to its
board of directors. Additionally, Bibhash Mukhopadhyay, Ph.D., has
stepped down from his role as a director.
“Alex’s deep commercial expertise gained from
his time at United Therapeutics and GSK coupled with his experience
leading Dova Pharmaceuticals into becoming a fully integrated
commercial-stage company will be an invaluable addition to our
already strong board,” said Jonathan P. Mow, chief executive
officer of PhaseBio. “Alex joins us at an ideal time in
PhaseBio’s growth as we continue to advance our clinical programs
and begin to shape our commercial strategy.”
Mr. Mow added, “I would also like to thank
Bibhash for his many contributions during his time as a director.
He was instrumental in helping PhaseBio get to where it is today
and continues to be one of the strongest champions of our
mission.”
Mr. Sapir has more than 25 years of experience
building commercial stage pharmaceutical organizations. He is
currently the chief executive officer of ReViral Therapeutics, an
antiviral company focused on discovering and developing
therapeutics to treat respiratory syncytial virus (RSV). He was
previously the president and chief executive officer at Dova
Pharmaceuticals, a pharmaceutical company focused on
developing and commercializing drug candidates for diseases where
there is a high unmet medical need. During his tenure, Mr. Sapir
led Dova’s transformation into a fully-integrated company with an
approved and marketed product, Doptelet® (avatrombopag), for the
treatment of thrombocytopenia. Mr. Sapir spent 10 years as
executive vice president for United Therapeutics Corporation, three
years as a consultant at ZS Associates, and seven years in various
commercial roles at GlaxoSmithKline. Mr. Sapir holds a B.A. in
economics from Franklin and Marshall College and an M.B.A. from
Harvard Business School.
“Having worked within the cardiopulmonary field
for much of my career, I am very passionate about the potentially
life-changing medicines PhaseBio is developing,” said Mr. Sapir. “I
am thrilled to join the PhaseBio board, and I look forward to
helping chart an exciting path forward for the company in bringing
much needed medicines to people with cardiopulmonary disease.”
In addition to joining the PhaseBio board, Mr.
Sapir was also appointed as a member of its audit committee.
About PhaseBioPhaseBio
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical
company focused on the development and commercialization of novel
therapies for cardiopulmonary diseases. The company’s pipeline
includes: PB2452, a novel reversal agent for the antiplatelet
therapy ticagrelor; PB1046, a once-weekly vasoactive intestinal
peptide receptor agonist for the treatment of pulmonary arterial
hypertension; and PB6440, an oral agent for the treatment of
resistant hypertension. PhaseBio’s proprietary ELP technology
platform enables the development of therapies with the potential
for less-frequent dosing and improved pharmacokinetics, including
PB1046, and drives both internal and partnership drug development
opportunities.
PhaseBio is located in Malvern,
PA and San Diego, CA. For more information, please
visit www.phasebio.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “anticipates,” “believes,”
“expects,” “intends,” “projects,” and “future” or similar
expressions are intended to identify forward-looking
statements.
Forward-looking statements include statements
concerning or implying the conduct or timing of our clinical
trials, and our research, development, regulatory and
commercialization plans. Forward-looking statements are based on
management's current expectations and are subject to various risks
and uncertainties that could cause actual results to differ
materially and adversely from those expressed or implied by such
forward-looking statements. Accordingly, these forward-looking
statements do not constitute guarantees of future performance, and
you are cautioned not to place undue reliance on these
forward-looking statements.
Risks regarding our business are described in
detail in our Securities and Exchange Commission filings,
including in our Quarterly Report on Form 10-Q for the quarter
ended September 30, 2019. These forward-looking statements
speak only as of the date hereof, and PhaseBio
Pharmaceuticals, Inc. disclaims any obligation to update these
statements except as may be required by law.
Investor Contact: John Sharp PhaseBio
Pharmaceuticals, Inc. Chief Financial Officer (610) 981-6506
john.sharp@phasebio.com
Media Contact:Jason SparkCanale
Communications(619) 849-6005jason@canalecomm.com
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Mar 2024 to Apr 2024
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Apr 2023 to Apr 2024